{
    "nct_id": "NCT06173362",
    "official_title": "A Pragmatic Phase II Study Evaluating Tolerability in Prostate Cancer Patients Treated With Abiraterone + Prednisone or Darolutamide",
    "inclusion_criteria": "* Ability to understand and willingness to sign an informed consent form\n* Histologically confirmed prostate adenocarcinoma\n* Advanced prostate cancer appropriate for treatment with abiraterone acetate plus prednisone or darolutamide as assessed by the treating physician\n* Participants are encouraged to be currently treated with androgen deprivation therapy (ADT) or having undergone bilateral orchiectomy\n* Performance status 0 - 2 (Karnofsky ≥ 50%)\n* Age ≥ 18 years at time of consent\n* Life expectancy ≥ 6 months per investigator discretion\n* Ability and stated willingness to adhere to the study visit schedule and other protocol procedures/requirements for the duration of the study\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have been on either abiraterone or darolutamide for > 28 days prior to initiating enrollment\n* Any condition that in the opinion of the investigator would prohibit the understanding or rendering of informed consent or interfere with the participant's safety or compliance while on trial",
    "miscellaneous_criteria": ""
}